相关实验视频
Updated: Jul 4, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
167
使用神经成像来研究大脑粉样血管病变及其与阿尔茨海默病的关系
Koral V Wheeler1, Andrei Irimia2,3, Meredith N Braskie1
1Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina Del Rey, CA, USA.
Journal of Alzheimer's disease : JAD
|February 2, 2024
概括
大脑粉样血管病变 (CAA) 有助于阿尔茨海默病 (AD) 的风险. 神经成像可以揭示CAA对AD进展的影响,并帮助发现生物标志物以改善诊断.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 血管痴呆症是一种精神疾病.
背景情况:
- 大脑粉样蛋白血管病变 (CAA) 涉及到大脑血管中的粉样蛋白-β沉积.
- CAA是阿尔茨海默病 (AD) 的重要血管因素,通常与AD同时发生.
- 需要进一步阐明CAA和AD病原体之间的相互作用,包括对粉样β和病理的相互影响.
研究的目的:
- 审查用于评估CAA in vivo的神经成像方法.
- 探索CAA标记物与AD脆弱性之间的关联.
- 确定研究途径,以推进CAA生物标志物发现和诊断能力.
主要方法:
- 对用于CAA评估的神经成像技术的审查.
- 通过神经成像检测到的CAA相关标记的讨论,如微型血液,BBB透性和改变的大脑血流.
- 探索这些标志物与AD病理之间的联系.
主要成果:
- 神经成像使CAA的体内评估成为可能,克服了基于尸检的研究的局限性.
- 识别的神经成像标志物包括出血,BBB干扰,脑血流减少,粉样蛋白/陶积累,白质变化和脑血管反应受损.
- 这些标志物可能表明CAA对AD风险和进展的影响.
结论:
- 神经成像对于理解CAA的自然史及其对AD认知衰退的影响至关重要.
- 对神经成像生物标志物的进一步研究可以提高CAA的诊断和分期.
- 研究这些标志物可能会使我们更好地了解AD的病原和易受伤害.
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193

